References
  1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med . 2009;361 (12): 1139-1151. doi:10.1056/NEJMoa0905561
  2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365 (10): 883-891. doi:10.1056/NEJMoa1009638
  3. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J . 2012; 76 (9): 2104-2111. doi:10.1253/circj.cj-12-0454
  4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2011;365 (11): 981-992. doi:10.1056/NEJMoa1107039
  5. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2013;369 (22): 2093-2104. doi:10.1056/NEJMoa1310907
  6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, Enhancing the diversity of clinical trial populations — eligibility criteria, enrollment practices, and trial design guidance for industry, November 2020.
  7. ICH Steering Committee, ICH harmonized tripartite guideline general considerations for clinical trials, 17 July 1997
  8. Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open . 2012; 2 (6): e001768. Published 2012 Dec 14. doi:10.1136/bmjopen-2012-001768
  9. Yoon CH, Park YK, Kim SJ, et al. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. Stroke . 2014;45 (10): 2983-2988. doi:10.1161/STROKEAHA.114.005599
  10. Hägg L, Johansson C, Jansson JH, Johansson L. External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. Cardiovasc Ther . 2014; 32 (5): 214-218. doi:10.1111/1755-5922.12087
  11. Desmaele S, Steurbaut S, Cornu P, Brouns R, Dupont AG. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients? Eur J Clin Pharmacol . 2016; 72 (9): 1125-1134. doi:10.1007/s00228-016-2078-1
  12. Fanning L, Ilomäki J, Bell JS, Dārziņš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol . 2017;73 (11): 1427-1436. doi:10.1007/s00228-017-2297-0
  13. Hughey AB, Gu X, Haymart B, et al. Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the ”Real-World” Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Thromb Thrombolysis . 2018; 46 (3): 316-324. doi:10.1007/s11239-018-1698-y
  14. Morimoto T, Uchida K, Sakakibara F, Kinjo N, Ueda S. Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice. Pharmacoepidemiol Drug Saf . 2021; 30 (10): 1321-1331. doi:10.1002/pds.5228
  15. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA . 2001; 285 (22): 2864-2870. doi:10.1001/jama.285.22.2864
  16. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest . 2010; 138 (5): 1093-1100. doi:10.1378/chest.10-0134
  17. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost . 2005; 3 (4): 692-694. doi:10.1111/j.1538-7836.2005.01204.x
  18. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation . 1987;76 (1):142-154. doi:10.1161/01.cir.76.1.142
  19. Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med . 2020;383 (18): 1735-1745. doi:10.1056/NEJMoa2012883
  20. Rothwell PM. External validity of randomised controlled trials: ”to whom do the results of this trial apply?” Lancet . 2005;365 (9453): 82-93. doi:10.1016/S0140-6736(04)17670-8